Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 44.5% in January

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 213,100 shares, a decrease of 44.5% from the December 31st total of 384,100 shares. Based on an average daily volume of 562,300 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.1% of the company’s shares are sold short.

Xilio Therapeutics Stock Down 2.9 %

Shares of Xilio Therapeutics stock opened at $0.69 on Friday. Xilio Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $1.93. The firm has a market cap of $30.55 million, a PE ratio of -0.40 and a beta of -0.25. The business’s fifty day moving average is $1.01 and its two-hundred day moving average is $0.94.

Xilio Therapeutics (NASDAQ:XLO) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Equities research analysts anticipate that Xilio Therapeutics will post -1.14 EPS for the current year.

Analyst Ratings Changes

Separately, Raymond James reduced their price target on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after acquiring an additional 155,337 shares during the last quarter. XTX Topco Ltd purchased a new position in Xilio Therapeutics in the second quarter valued at about $32,000. Finally, Renaissance Technologies LLC raised its position in Xilio Therapeutics by 18.3% in the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after purchasing an additional 45,554 shares during the period. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.